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Adrenomedullin reduces mesangial cell number and glomerular
inflammation in experimental mesangioproliferative glomeru-
lonephritis.
Background. Adrenomedullin (ADM) is a vasodilator pep-
tide that is abundantly expressed in the kidney. ADM has an-
tiproliferative effects on glomerular mesangial cells (MC) in
vitro. Whether or not treatment with ADM can reduce MC
proliferation in vivo [i.e., in mesangioproliferative glomeru-
lonephritis (GN)] is unknown. We tested the hypothesis that
ADM substitution reduces MC proliferation in GN.
Methods. GN in rats was induced by injection of an anti-Thy-
1.1 antibody. Rats received osmotic minipumps, which contin-
uously delivered rat ADM (500 ng/hour, N = 11), or vehicle
(N = 13) from day 3 to day 6 after GN induction. Rats were
sacrificed 6 days after induction of GN. On kidney sections, cells
staining positive for proliferating cell nuclear antigen, mesan-
gial cells, monocytes, and apoptotic cells were counted. Parame-
ters of inflammation and fibrosis were measured in renal cortex
and sieved glomeruli by real-time polymerase chain reaction
(PCR).
Results. Systolic blood pressure, diuresis, albuminuria, cre-
atinine clearance, microaneurysm formation, and mesangial
matrix expansion were not influenced by ADM infusion. How-
ever, ADM treatment significantly reduced the number of MC,
showed a tendency to reduce total glomerular cell prolifera-
tion, and significantly increased apoptosis. ADM-treated GN
animals showed significantly less glomerular monocyte infiltra-
tion. ADM treatment normalized transforming growth factor
(TGF)-b1 mRNA expression and reduced monocyte chemoat-
tractant protein-1 (MCP-1), osteopontin, plasminogen activator
inhibitor-1 (PAI-1), collagen I, and collagen III mRNA expres-
sion significantly.
Conclusion. Exogenous ADM infusion reduces MC number
and glomerular monocyte infiltration in the state of mesangial
proliferation during acute experimental mesangioproliferative
GN. These findings indicate that ADM can influence the course
of mesangioproliferative GN.
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Adrenomedullin (ADM) is a 52 amino acid peptide
originally isolated from human pheochromocytoma [1].
ADM is a potent vasodilator and is expressed in various
organs throughout the body, where it exerts systemic and
local effects. In the kidney, ADM is produced in glomeru-
lar endothelial cells, vascular smooth muscle cells, dis-
tal and collecting tubules [2]. Production of ADM in
mesangial cells was shown in vitro, and by immunohis-
tochemistry in vivo. A constitutive synthesis and prompt
secretion of ADM in mesangial cells was postulated [2].
In most cell types, ADM acts via a G-protein–coupled,
calcitonin receptor–like receptor that is modified by re-
ceptor activity modifying proteins 2 and 3 (RAMP) [3].
In vitro, ADM relaxes mesangial cells via cAMP. ADM
reduces the generation of reactive oxygen species by
mesangial cells [4] and inhibits angiotensin II induced
migration and proliferation of mesangial cells [5]. A dose-
dependent antiproliferative effect of ADM on mesan-
gial cells in vitro was shown by others [5, 6] and by
our group [7]. Intrarenal ADM infusion induces renal
vasodilatation and natriuresis [2]. In hypertensive rat
models, human ADM gene delivery attenuated hyper-
tension, myocardial infarction, renal injury and cardio-
vascular remodelling via cAMP and cGMP pathways
[8–10]. Chronic ADM infusion exerts renoprotective
activity even without reduction of the systemic blood
pressure. Infusion of human ADM at a nonhypotensive
dose of 500 ng/hr significantly reduced glomeruloscle-
rosis and inflammation in Dahl–salt-sensitive rats [11]
and in DOCA–salt-treated rats [12]. Those data suggest
that ADM plays an important role in the regulation of
mesangial cell turnover, and protects from intraglomeru-
lar mechanical stress and inflammation [2]. Nevertheless,
antiproliferative properties of ADM on mesangial cells
in vivo have hitherto not been studied in detail.
In a rat model of acute mesangioproliferative glomeru-
lonephritis (GN), a single injection of anti-Thy1.1
antibody causes an acute, complement-mediated mesan-
giolysis lasting approximately for 2 days. This is followed
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by mesangial proliferation and overproduction of mesan-
gial matrix during day 3 to 10. In contrast to human
mesangioproliferative glomerulonephritis, the acute anti-
Thy1.1 model results in almost complete remission [13].
Matsumoto et al showed that glomerular ADM systhesis
is unchanged in the state of acute mesangial proliferation
on day 7 in this model, but demonstrated an up-regulation
in the phase of reparation [14].
Therefore, we tested the hypothesis that ADM reduces
mesangial cell proliferation in a rat model of mesan-
gioproliferative glomerulonephritis. We administered rat
ADM in a nonhypotensive dose to rats 3 days after in-
duction of acute anti-Thy1.1 nephritis during the peak of
mesangial proliferation, and analyzed glomerular mesan-
gial cell number and parameters of inflammation and fi-
brosis after 3 days of ADM treatment.
METHODS
Experimental disease and adrenomedullin treatment
Male Sprague-Dawley rats (170 to 200 g) were obtained
from Charles River Deutschland (Sulzfeld, Germany).
Rats were housed in a room maintained at 22 ± 2◦C,
exposed to a 12-hour dark/light cycle. The animals were
allowed unlimited access to standard chow (#1320, Al-
tromin, Lage, Germany) and tap water. All procedures
performed on animals were done in accordance with
guidelines of the American Physiological Society, and
were approved by the local government authorities
(Regierung von Mittelfranken, AZ # 621–2531.31–11/02).
The rats were divided into 4 groups: nephritic rats with
ADM treatment (GN+ADM; N = 11), nephritic rats
treated with vehicle (GN+VEH; N = 12), control animals
with ADM treatment (CO+ADM; N = 5), and control
animals treated with vehicle (GN+VEH, N = 5).
Anti-Thy1.1 nephritis was induced by a single intra-
venous injection of 1 mg/kg body weight monoclonal
anti-Thy1.1 antibody (ER4; Antibody Solutions, Palo
Alto, CA, USA) into the tail vein. In this model, the
monoclonal antibody against the Thy1.1 antigen on rat
mesangial cells induces acute complement-mediated
mesangiolysis, followed by mesangial proliferation and
glomerular reparation over a period of 3 weeks [13]. Con-
trol animals were injected isotonic saline. On day 3 after
induction of anti-Thy1.1 nephritis, the animals received
osmotic minipumps (Alzet model 2001; Alza Scientific
Products, Palo Alto, CA, USA) subcutaneously, which
continuously delivered recombinant rat ADM (H5694;
Bachem AG, Weil am Rhein, Germany) 500 ng/hour,
or vehicle (aqua injectable; VEH) from day 3 to day
6 of disease. Twenty-four hours before sacrifice, urine
was collected for quantification of albumin excretion
by enzyme-linked immunosorbent assay (ELISA; Cell
Trend, Luckenwalde, Germany). At the day of sacrifice,
all animals were instrumented with femoral catheters for
intra-arterial blood pressure measurements as described
previously [15]. Blood pressure was measured in con-
scious rats 2 hours after anesthesia.
Rats were sacrificed and the kidneys were decapsu-
lated. Portions of the kidney cortex were immediately
snap-frozen in liquid nitrogen for mRNA analysis. An-
other portion of renal tissue was fixed in methyl-Carnoy
solution (60% methanol, 30% chloroform, and 10%
glacial acetic acid). A third portion of the kidneys was
used to isolate glomeruli by the sieving technique at 4◦C
for extraction of glomerular mRNA, as described previ-
ously [16]. Creatinine and blood urea nitrogen (BUN)
in the serum and urine samples were analyzed with the
automatic analyser Integra 800 (Roche, Mannheim, Ger-
many). Endogenous creatinine clearance was calculated.
RNA extraction and real-time PCR
RNA was extracted from renal cortex or isolated
glomeruli using Trizol reagent (Invitrogen, Paisley, Scot-
land, UK) according to the manufacturer’s instruc-
tions. Quantitative real-time reverse transcription poly-
merase chain reaction (RT-PCR) analysis was performed
as described previously [7] for transforming growth
factor-b1 (TGF-b1), monocyte chemoattractant protein-
1 (MCP-1) and plasminogen activator inhibitor-1 (PAI-
1). In probes of cortical tissue, the relative amount
of the specific mRNA was normalized with respect to
porphobilinogen-desaminase (PBGD). The results were
confirmed by normalization to other “housekeeping
genes” like b-actin or glyceraldehyde-3-phosphate de-
hydrogenase (GAPDH) (data not shown). In mRNA
probes of pooled sieved glomeruli, GAPDH was used as
“housekeeping gene.” Results were confirmed by similar
results using b-actin as “housekeeping gene” (data not
shown). With the exception of osteopontin (OSP) [17],
the oligonucleotides for each gene investigated were de-
signed by the Primer Express software (Perkin-Elmer,
Foster City, CA, USA), using uniform selection parame-
ters that allowed for the application of standard cycle con-
ditions. The designed primers and TaqMan probes used
are listed in Table 1.
Collagen I and III mRNA expression was quantified by
the SYBR Green method. The relative amount of the spe-
cific mRNA was normalized with respect to 18S rRNA.
Normalization to GAPDH as second housekeeping was
done for confirmation (data not shown). Primers and cy-
cling conditions are described elsewhere [18]. Primers
used for amplification of 18S cDNA were forward 5′-
TTGATTAAGTCCCTGCCCTTTGT-3′ and reverse 5′-
CGATCCGAGGGCCTCACTA-3′.
Kidney histology
For evaluation of renal histology, 3-lm sections of
paraffin-embedded kidney tissue were periodic acid–
Schiff (PAS) stained. Glomerular mitotic bodies were
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Table 1. Designed primers and TaqMan probes used in this study
TGF- b1 forward 5′-CACCCGCGTGCTAATGGT-3′
reverse 5′-GGCACTGCTTCCCGAATG-3′
probe 5′(FAM)- ACCGCAACAACGCAATCTATGACA-(TAMRA)3′
MCP-1 forward 5′- CCTCCACCACTATGCAGGTCTC-3′
reverse 5′- GCACGTGGATGCTACAGGC -3′
probe 5′(FAM)- TCACGCTTCTGGGCCTGTTGTTCA-(TAMRA)3′
PAI-1 forward 5′-TCCGCCATCACCAACATTTT-3′
reverse 5′-GTCAGTCATGCCCAGCTTCTC-3′
probe 5′(FAM)-CCGCCTCCTCATCCTGCCTAAGTTCTCT-(TAMRA)3′
PBGD forward 5′-AGACCATGCAGGCCACCA-3′
reverse 5′-CAACCAACTGTGGGTCATCCT-3′
probe 5′(FAM)- AGGTCCCTGTTCAGCAAGAAGATGGTCC-(TAMRA)3′
b-actin forward 5′- TGAGCTGCCTGACGGTCAG-3′
reverse 5′-TGCCACAGGATTCCATACCC-3′
probe 5′(FAM)- CACTATCGGCAATGAGCGGTTCCG-(TAMRA)3′
GAPDH forward 5′-ACGGGAAACCCATCACCAT-3′,
reverse 5′-CCAGCATCACCCCATTTGA-3′
probe 5′(FAM)-TTCCAGGAGCGAGATCCCGTCAAG-(TAMRA)3′
counted in all glomeruli of a given PAS-stained kidney
section (100–200 glomeruli, no selection) and expressed
as cells per glomerular cross-section [19]. To assess the ex-
tent of the formation of microaneurysms, capillary widen-
ing was scored. A score 0 to 4 was applied. Score 0: no
capillary widening in the glomerular tuft, score 1: capil-
lary widening involving up to 25% of the glomerular tuft,
score 2: capillary widening 25% to 50%, score 3: capil-
lary widening 50% to 75%, score 4: capillary widening
involving more than 75% of the glomerular tuft [20].
Immunohistochemistry
After overnight fixation in methyl-Carnoy solution, tis-
sues were dehydrated by bathing in increasing concentra-
tions of methanol, followed by 100% isopropanol. After
embedding in paraffin, 3-lm sections were cut with a Leitz
SM 2000 R microtome (Leica Instruments, Nussloch,
Germany). After deparaffinization, endogenous peroxi-
dase activity was blocked with 3% H2O2 in methanol for
20 minutes at room temperature. Glomerular collagen I
was detected by a rabbit polyclonal antibody (Biogene-
sis, Poole, England, UK) at a dilution of 1:1000. A goat
polyclonal antibody to collagen IV (Southern Biotech-
nology Associates, Birmingham, AL, USA) was used at
a dilution of 1:500. A mouse monoclonal antibody de-
tecting proliferating cells (PCNA) was purchased from
DAKO (Hamburg, Germany) and used at a dilution of
1:50. The mouse monoclonal antibodies to macrophages
(ED-1) and to mesangial cells (OX-7) were from Serotec
(Biozol, Eching, Germany) and diluted 1:250 or 1:1000,
respectively.
Immunohistochemistry was performed in deparaf-
finized sections of methyl-Carnoy–fixed kidneys, using an
avidin horseradish peroxidase detection system (Vector
Laboratories, Burlingame, CA, USA) as described be-
fore [21]. As a negative control, we used equimolar con-
centrations of preimmune goat or mouse immunoglobu-
lin G. Each slide was counterstained with hematoxylin.
For detection of apoptotic cells we used an In Situ Cell
Death Detection Kit (TUNEL staining; Roche Diagnos-
tics GmbH, Penzberg, Germany) on deparaffinized sec-
tions of methyl-Carnoy–fixed kidneys according to the
manufacturer’s instructions.
Analysis of data
Proliferating cells (PCNA-positive cells), mesangial
cells (OX-7–positive cells), macrophages (ED-1–positive
cells), or apoptotic cells (TUNEL staining) were counted
in all glomeruli of a given kidney section (100–200
glomeruli, no selection) and expressed as cells per
glomerular cross-section. To evaluate glomerular colla-
gen I and IV, respectively, computer-based integration
of stained areas was performed in 20 randomly selected
glomeruli per kidney section (Metaview, Visitron Sys-
tems, Puchheim, Germany). The average area staining
positive for collagen I and IV was calculated as a percent-
age of total glomerular area [20]. The results of RT-PCR
were expressed as induction of mRNA expression com-
pared to the mean expression level in VEH-treated CO
animals. This expression was defined as 1.0-fold induc-
tion.
One-way analysis of variance (ANOVA), followed by
post-hoc Bonferroni test with adjustment for multiple
comparisons, was used to test significance of differences
between groups. A P value less than 0.05 was consid-
ered significant. The procedures were carried out using
the Graph Pad Prism software (GraphPad Software, San
Diego, CA, USA). Values are displayed as means ± stan-
dard error of the mean.
RESULTS
Physiologic profiles, urinary parameters
Body weight of GN animals at the end of experiment
was significantly lower than in CO animals, but there
was no difference in body weight gain during ADM or
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Table 2. Physiologic profiles and urinary parameters at day 6 of anti-Thy1.1 nephritis after 3 days of continuous ADM infusion (GN+ADM) in
comparison to vehicle-treated animals (GN+VEH) and controls (CO+ADM, CO+VEH)
GN+ADM GN+VEH CO+ADM CO+VEH
(N = 11) (N = 12) (N = 5) (N = 5)
Body weight (BWT) at day 6 of GN g 235.7 ± 3.2 232.4 ± 3.8c 249.6 ± 5.3 252.3 ± 6.4
Body weight gain during ADM therapy g/day 51.6 ± 1.8 47.8 ± 2.7 60.8 ± 4.1 64.4 ± 3.3
Urinary volume lL/g BWT/24h 177 ± 42 112 ± 26 120 ± 30 65 ± 7
Water intake mL/hr/100 g BWT 0.26 ± 0.04 0.20 ± 0.02 0.21 ± 0.03 0.16 ± 0.01
Mean arterial pressure mm Hg 112 ± 2 104 ± 5 109 ± 6 105 ± 3
Heart rate per min 450 ± 19 413 ± 11 412 ± 17 475 ± 14
Creatinine clearance mL/hr/100 g BWT 54.0 ± 3.7 39.1 ± 4.4a 75.9 ± 7.6 96.8 ± 7.3
BUN mg/dL 32.3 ± 2.9 37.5 ± 4.6c 26.3 ± 4.2 19.6 ± 1.5
Proteinuria mg/24h 60.2 ± 12.8 84.3 ± 17.3c 12.5 ± 1.7 13.56 ± 1.9
Albuminuria lg/mg albumin/creatinine 272.4 ± 45.8 400.6 ± 91.5b 5.4 ± 2.2 2.9 ± 1.1
Sodium excretion mmol/24h 5.45 ± 1.23 2.92 ± 1.05 2.72 ± 0.92 0.78 ± 0.12
Kidney weight mg/g BWT 8.2 ± 0.2 8.9 ± 0.3b 6.8 ± 0.1 7.4 ± 0.2
BWT, body weight. Values are given as mean ± standard error of the mean.
a P < 0.001, bP < 0.01, and cP < 0.05 for the difference between GN+VEH and CO+VEH.
VEH treatment (Table 2). There were no significant dif-
ferences in water intake and urinary output between the 4
groups. ADM treatment tended to increase mean sodium
excretion in GN and CO animals, but the differences did
not reach statistical significance. Endogenous creatinine
clearance was significantly lower in GN+VEH animals
than in CO+VEH animals, but ADM treatment did not
change creatinine clearance in GN+ADM animals. Kid-
ney weight was significantly higher in GN animals com-
pared to CO. ADM treatment had no significant effect
on the kidney weight. As expected, GN induced protein-
uria and albuminuria, which was not significantly reduced
by ADM. In the dose applied, ADM treatment neither
influenced the arterial systolic blood pressure in CO ani-
mals nor in GN animals. The heart rate was similar in all
4 groups.
Mesangial cell number
As expected on day 6 of GN, the number of mesan-
gial cells (i.e., OX-7–positive glomerular cells) was signif-
icantly higher in GN animals than in CO animals. ADM
significantly reduced the number of mesangial cells com-
pared to GN+VEH animals (Fig. 1). The total number
of proliferating cells (i.e., PCNA-positive cells) in the
glomeruli was significantly higher in GN animals than
in CO. ADM treatment resulted in a nonsignificant re-
duction of glomerular cell proliferation in GN animals
(Fig. 2A). Thy1.1.-antibody injection induced mitosis of
glomerular cells. The number of mitotic cells tended
to be lower in ADM treated GN animals versus VEH
treated GN animals (Table 3). In GN animals, the number
of apoptotic cells per glomerulus (i.e., TUNEL-positive
cells) was significantly higher than in CO animals. ADM
treatment in GN animals significantly increased apop-
tosis in glomerular cells compared to VEH-treated GN
animals (Fig. 2B).
Glomerular inflammation
GN animals showed marked glomerular infiltration
by ED1-positive monocytes. In ADM-treated GN ani-
mals, monocyte infiltration was significantly less than in
VEH-treated GN animals (Fig. 3A). ADM treatment
neither influenced the number of glomerular microa-
neurysms (Table 3) nor the number of lesions bigger
than 50% of glomerular diameter (score 3 and 4, data
not shown). In GN animals, cortical MCP-1 mRNA ex-
pression showed an 8-fold increase in renal cortex. ADM
treatment reduced MCP-1 mRNA expression by more
than 50% in GN animals (Fig. 3B). In mRNA probes
from pooled sieved glomeruli, MCP-1 mRNA showed a
2.7-fold induction in GN animals. ADM treatment nor-
malized glomerular MCP-1 mRNA expression (0.8-fold
induction compared to controls). OSP mRNA expression
in cortical tissue reached a 43.5-fold induction in GN an-
imals. In ADM-treated GN animals, OSP expression was
reduced to 6.7-fold induction compared to controls (Fig.
3C). OSP mRNA expression in sieved glomeruli reached
a 2.6-fold induction by GN induction. In ADM-treated
GN animals, glomerular OSP mRNA expression was re-
duced to control levels (1.1-fold induction). ADM treat-
ment in CO animals altered neither glomerular mono-
cyte infiltration nor MCP-1 and OSP mRNA expression
(Fig. 3).
Parameters of extracellular matrix expansion
GN induction resulted in a 3-fold increase of cortical
TGF-b1 mRNA expression. ADM treatment lowered the
TGF-b1 expression to control level (Fig. 4A). In mRNA
extracted from pooled, sieved glomeruli, TGF-b1 showed
2.1-fold over expression in GN rats compared to non-
nephritic controls. In ADM-treated GN animals, mRNA
expression of TGF-b1 was reduced to control levels (1.1-
fold induction).
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Fig. 1. Number of glomerular mesangial
cells. Representative photomicrographs of
glomeruli stained for OX7 and number of
mesangial cells (staining for OX-7) on day 6
of anti-Thy1.1 nephritis after 3 days of contin-
uous ADM infusion (GN+ADM) in compar-
ison to vehicle-treated animals (GN+VEH)
and controls (CO+ADM, CO+VEH) (mag-
nification 1:400).
Cortical PAI-1 mRNA expression was 20.8 times
higher in GN animals than in CO animals. ADM treat-
ment in GN animals reduced the cortical expression of
PAI-1 mRNA to a 5.6-fold induction compared to un-
treated controls (Fig. 4B). In sieved glomeruli PAI-1,
mRNA expression was 7.2 times higher in GN animals
than in CO animals. ADM treatment in GN animals re-
sulted in a reduction to a 1.9-fold induction.
Cortical collagen I mRNA expression showed a 6.4-
fold induction in GN animals compared to CO ani-
mals. In ADM-treated GN animals, the induction of col-
lagen I mRNA was significantly lower than in VEH-
treated GN animals (Fig. 4C). In pooled, sieved glomeruli
of GN+VEH animals, collagen I mRNA expression
reached a 560-fold induction compared to a 96-fold in-
duction in GN+ADM animals.
Cortical collagen III mRNA expression in GN animals
was significantly reduced by ADM treatment (Fig. 4D).
Glomerular expression of collagen III mRNA reached a
72-fold induction in the GN+VEH group and a 43-fold
induction in the GN+ADM group compared to controls.
Nevertheless, the amount of glomerular collagen I and
collagen IV protein was not significantly different be-
tween ADM- and vehicle-treated GN animals (Table 3)
at the time of investigation.
ADM application in CO animals did not influence
any of the analyzed parameters for glomerular matrix
expansion.
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Fig. 2. Proliferation and apoptosis. Number
of PCNA positive glomerular cells (A) and
apoptotic glomerular cells (TUNEL stain-
ing) (B) at day 6 of anti-Thy1.1 nephri-
tis after 3 days of continuous ADM infu-
sion (GN+ADM) in comparison to vehicle-
treated animals (GN+VEH) and controls
(CO+ADM, CO+VEH).
Table 3. Histologic profiles on day 6 of anti-Thy1.1 nephritis after 3 days of continuous ADM infusion (GN+ADM) in comparison to
vehicle-treated animals (GN+VEH) and controls (CO+ADM, CO+VEH)
GN+ADM GN+VEH CO+ADM CO+VEH
(N = 11) (N = 12) (N = 5) (N = 5)
Score for microaneurysms 1.32 ± 0.21 1.22 ± 0.13a 0.15 ± 0.04 0.19 ± 0.05
Mitosis(mitotic cells/100 glomerular cross sections) 2.1 ± 0.4 2.7 ± 0.4a 0.9 ± 0.4 1.0 ± 0.3
Collagen I(percentage of total glomerular area stained positive) 3.69 ± 0.83 5.12 ± 0.83a 0.02 ± 0.02 0.0 ± 0.0
Collagen IV(percentage of total glomerular area stained positive) 17.14 ± 1.71 18.33 ± 1.62a 7.64 ± 1.81 8.53 ± 1.66
Values are given as mean ± standard error of the mean.
aP < 0.01 for the difference between GN+VEH and CO+VEH.
DISCUSSION
In our experiments, anti-Thy1.1 antibody injection re-
sulted in prominent mesangial proliferation at day 6
in the untreated group. ADM treatment reduced the
number of mesangial cells significantly. Glomerular cell
proliferation tended to be reduced in ADM-treated GN
animals compared to GN+VEH, but failed to reach sta-
tistical significance. On the other hand, the number of
apoptotic cells in glomeruli was increased by ADM treat-
ment in GN animals. In vitro, a dose-dependent antipro-
liferative effect of ADM on mesangial cells is well known
[4, 6, 22–25]. Furthermore, ADM increases apoptosis in
mesangial cells [6, 7]. Since mesangial cells secrete ADM
[26] and express receptors responsive to ADM [27], an
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Fig. 3. Glomerular inflammation. Number of
glomerular ED1-positive cells (A) and in-
duction of MCP-1 (B) and OSP mRNA ex-
pression (C) relative to untreated control
animals at day 6 of anti-Thy1.1 nephritis
after 3 days of continuous ADM infu-
sion (GN+ADM) in comparison to vehicle-
treated animals (GN+VEH) and controls
(CO+ADM, CO+VEH). mRNA expression
of MCP-1 and OSP is normalized on PBGD
mRNA expression.
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Fig. 4. Profibrotic parameters. TGF-b1 (A), PAI-1 (B), collagen I (C), and collagen III (D) mRNA expression relative to untreated control animals
in renal cortex at day 6 of anti-Thy1.1 nephritis after 3 days of continuous ADM infusion (GN+ADM) in comparison to vehicle-treated animals
(GN+VEH) and controls treated with ADM (CO+ADM). Expression is normalized on PBGD mRNA expression.
autocrine/paracrine effect of ADM on the regulation of
proliferating mesangial cells seems possible in vitro and
in vivo.
In the anti-Thy1.1 model, mesangial proliferation is
mandatory for reparation of the mesangial injury [28].
On the other hand, mesangial cell proliferation is an
important step in the process leading to glomerular
scarring in chronic glomerulonephritis (induced, e.g., by
repeated anti-Thy1.1 treatment in uninephrectomized
animals) [29]. Apoptosis of mesangial cells seems to coun-
terbalance excessive proliferation during repair in the
anti-Thy1.1 model [29].
Injection of ADM to the renal artery increases re-
nal blood flow, glomerular filtration rate, urine, and salt
excretion [2]. Continuous administration of 1000 ng/hr
ADM over 4 days significantly reduced blood pressure
in rats with renovascular hypertension [30]. ADM gene
delivery to spontaneously hypertensive rats, Dahl–salt-
sensitive, DOCA-salt and two-kidney one-clip hyperten-
sive rats attenuated hypertension as well as glomeru-
losclerosis and tubular lesions [9]. Elevated levels of
adenylate cyclase and cGMP were measurable, indicating
the cAMP and/or NO-cGMP pathway to be involved in
the mediation of ADM effects [9]. Mori et al [12] chose
a nonhypotensive dose of 500 ng/hr ADM, and showed
renoprotective effects of long-term subcutaneous infu-
sion of human ADM in hypertensive rats with plasma
ADM levels over 0.5 pmol/L. Chronic ADM infusion re-
duced glomerular sclerosis without reducing blood pres-
sure in hypertensive rats [11, 12].
Therefore, we chose an ADM dose of 500 ng/hr. As
expected, there was no significant impact on mean arterial
blood pressure, glomerular filtration rate, urinary output,
and natriuresis, neither in nephritic nor in control animals.
In our study, ADM treatment reduced glomerular
monocyte infiltration and MCP-1 and OSP mRNA ex-
pression in GN animals. An anti-inflammatory potency
of ADM is known from other models of inflammation. In
neonatal piglets with acute respiratory distress syndrome
due to surfactant depletion [31], aerosolized ADM de-
creased TGF-b1 and IL-1b expression [32]. Similar pos-
itive effects have been observed in rats with peritonitis
due to acetic acid [33].
ADM has an impact on glomerular matrix expansion
and fibrosis via TGF-b1. In hypertension models [12]
and in other inflammatory animal models [32], ADM
treatment reduced TGF-b1 expression. Overexpression
of TGF-b 1 [34] and PAI-1 [35] in anti-Thy1.1 nephri-
tis is well known. TGF-b1 and PAI-1 play an essential
role in the induction of fibrotic lesions and renal scarring
[36, 37]. Our data showed a normalization of TGF-b 1
and PAI-1 mRNA expression by ADM treatment. Fur-
thermore, collagen I and collagen III mRNA expression
were significantly reduced. By immunohistochemistry,
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the glomerular area positive for collagen I and III pro-
tein was not affected by ADM treatment until day 6. We
cannot exclude effects at later time points. In anti-Thy1.1
nephritis, collagen I mRNA expression precedes the ap-
pearance of type I collagen protein for some days [38].
Collagen protein accumulation is modulated by produc-
tion as well as degradation of collagens. At least the tran-
scriptional regulation of collagen production was clearly
attenuated by ADM. Acute anti-Thy 1.1 nephritis is well
suited to study changes in mesangial proliferation, but it is
limited in the analysis of fibrosis. Future studies of ADM
treatment in chronic anti-Thy1.1 nephritis could help to
answer the question whether or not ADM treatment has
antifibrotic properties in this model.
IgA nephropathy is a mesangioproliferative glomeru-
lonephritis in man, and is the most common primary
glomerulonephritis in the world [39]. The role of the
ADM system in IgA nephropathy is still unclear. Plasma
levels of ADM in patients with IgA nephropathy were
higher or unchanged compared to healthy controls [2].
Urinary levels of ADM were decreased in all studies
on IgA nephropathy, but did not correlate with serum
levels [2]. Therefore, renal production as a source for
urinary ADM, and a lack of renal ADM production dur-
ing IgA nephropathy, has been postulated [2]. Moreover,
Kubo et al [40] could show a decreased gene transcrip-
tion in peripheral blood mononuclear cells in patients
with IgA nephropathy. Obviously, none of these mea-
surements convincingly reflect local ADM levels. It is
presently not clear whether ADM would be useful to
treat children or adults with a chronic course of this dis-
ease. Until now, ADM has been used with some success
in patients with pulmonary hypertension [41] and con-
gestive heart failure [42]. Intravenous injection of ADM
resulted in a reduction of pulmonary resistance, systemic
blood pressure, increased cardiac index, urinary sodium
excretion, and urine volume.
CONCLUSION
Our study demonstrates that ADM influences mesan-
gial cell number during the peak of mesangial cell pro-
liferation in a model of mesangioproliferative glomeru-
lonephritis in vivo. Furthermore anti-inflammatory and
antifibrotic effects were detected. Future studies may
have to address whether ADM may influence renal scar-
ring, and whether it can be used to treat mesangioprolif-
erative glomerulonephritis in humans.
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